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Background: Feline morbillivirus (FeMV) is associated with the presence of tubulo-interstitial
nephritis (TIN) in cats, however the seroprevalence of FeMV in the UK and the association
between the presence of FeMV and renal azotemia is unknown
Hypothesis/Objectives: To identify whether paramyxoviruses are present in urine samples of
geriatric cats and to develop an assay to assess FeMV seroprevalence. To investigate the relation-
ship between both urinary paramyxovirus (including FeMV) excretion and FeMV seroprevalence
and azotemic chronic kidney disease (CKD).
Animals: Seventy-nine cats (40 for FeMV detection; 72 for seroprevalence).
Methods: Retrospective cross-sectional, case control study. Viral RNA was extracted from urine
for RT-PCR. PCR products were sequenced for virus identification and comparison. The FeMV N
protein gene was cloned and partially purified for use as an antigen to screen cat sera for anti-
FeMV antibodies by Western Blot.
Results: Feline morbillivirus RNA from five distinct morbilliviruses were identified. Detection was
not significantly different between azotemic CKD (1/16) and nonazotemic groups (4/24; P5 .36).
Three distinct, non-FeMV paramyxoviruses were present in the nonazotemic group but their
absence from the azotemic group was not statistically significant (P5 .15). 6/14 (43%) azotemic
cats and 40/55 (73%) nonazotemic cats were seropositive (P5 .06).
Conclusions and Clinical Importance: Feline morbillivirus was detected in cats in the UK for the
First time. However, there was no association between virus prevalence or seropositivity and
azotemic CKD. These data do not support the hypothesis that FeMV infection is associated with
the development of azotemic CKD in cats in the UK.
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Abbreviations: CDV, canine distemper virus; CKD, chronic kidney disease; CRFK, Crandell-Rees feline kidney; FLUTD, feline lower urinary tract disease; FeMV,
feline morbillivirus; GFR, glomerular filtration rate; IRIS, International Renal Interest Society; PCR, Polymerase Chain Reaction; RT-PCR, Reverse Transcription
Polymerase Chain Reaction; SDMA, symmetric dimethylarginine; SDS-PAGE, Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis; TT4, total thyroxine;
TIN, tubulointerstitial nephritis; UAC, urine albumin: creatinine ratio; UCC, urine cystatin C: creatinine ratio; UPC, urine protein: creatinine ratio; USG, urine
specific gravity; WB, Western blot.
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1 | INTRODUCTION
Feline morbillivirus (FeMV), family Paramyxoviridae, was originally dis-
covered in Hong Kong in 2012. Sequencing and phylogenetic analyses
confirmed that FeMV is a distinct virus species.1 Paramyxoviruses are
enveloped, single-stranded, negative RNA viruses, which have been
previously identified in a wide variety of vertebrate hosts.2 Upon dis-
covery, the presence of FeMV was associated with histopathologically
confirmed tubulointerstitial nephritis (TIN) in stray cats1 and the virus
has since been detected in the urine of cats in Japan, Germany, Italy,
USA, South America, and Turkey.3–10 Furthermore, there is an associa-
tion between paramyxoviruses and renal pathology in a range of
species, including humans,11 rats,12 bats,13 and squirrels.14 Tubulo-
interstitial nephritis is the most common lesion in cats with chronic kid-
ney disease (CKD)15 and FeMV RNA is more prevalent in renal tissues
of cats with TIN compared with blood and urine samples from the
same animals.5 Furthermore, in-vitro studies of Crandell-Rees Feline
Kidney (CRFK) cells inoculated with known FeMV positive samples
have demonstrated virus replication and cytopathic effects, including
syncytium formation,1,4 and immunohistochemistry has detected the
presence of FeMV N protein in renal tubular cells.1,10,16 However, at
time of writing, no studies have evaluated if FeMV is more prevalent in
cats with biochemically confirmed azotemic CKD compared with nona-
zotemic cats.
CKD is a common condition of older cats, with a 4% prevalence in
UK 1st opinion practice.17 Current treatment protocols have limited
efficacy and therefore, CKD is an important cause of morbidity and
mortality in geriatric cats.18 The etiopathogenesis of TIN in cats with
CKD is unclear at present, and determination of risk factors for CKD
could help to further clarify the inciting factors that lead to TIN and
CKD in cats, which could in turn lead to better preventative strategies,
such as vaccination.
The primary aims of our study were to (1) identify if paramyxovi-
ruses (including FeMV) are present in the urine of cats in the UK, (2) to
develop a serological assay to establish if there is evidence of exposure
of UK cats to FeMV, and (3) to evaluate if a relationship exists between
the presence of azotemic CKD and the detection of serum anti-FeMV
antibodies, the urinary excretion of paramyxoviruses (including FeMV)
or both.
2 | MATERIALS AND METHODS
2.1 | Sample selection
A free-of-charge screening programme at three UK 1st-opinion
practices between March 1, 2013 and April 30, 2015 was designed to
collect urine samples from cats with and without azotemic CKD. This
protocol was approved by the Ethics and Welfare Committee at the
Department of Veterinary Medicine, University of Cambridge (CR56).
Blood samples were obtained by jugular venipuncture and urine sam-
ples were taken by cystocentesis. A commercial laboratory analyzed
complete blood count, serum biochemistry, including total thyroxine
concentration (TT4) and urinalysis, including measurement of urine
specific gravity (USG) by refractometry, urine dipstick, sediment analy-
sis and UPC. Cats with CKD were staged according to the IRIS guide-
lines for cats with CKD.19
To be included in the study, cats were aged8 years old with no
significant systemic disease (eg, diabetes mellitus or hyperthyroidism).
Exclusion criteria included recent or ongoing treatment with corticoste-
roids, diuretics, or angiotensin-converting enzyme inhibitors, and recent
or concurrent IV fluid treatment at the time of sampling. Samples were
excluded from the study if TT4 >40 nmol/L, if urine samples were
older than 3 days at the time of analysis, if there was evidence of sig-
nificant systemic illness on complete blood count or biochemistry or if
there was evidence of lower urinary tract inflammation on urinalysis
(pyuria, bacteriuria, and hematuria).
Excess urine was stored at 2808C until batch RNA isolation. Renal
azotemia was diagnosed by documentation of an increased concentra-
tion of serum creatinine in conjunction with reduced urine concentrating
ability.20 Cats were assigned to either the azotemic CKD group (defined
as serum creatinine concentration >1.7 mg/dL or 153 mmol/L (the upper
limit of our laboratory reference interval) and concurrent USG<1.035)
or the nonazotemic group. Table 1 summarizes the results for the cat
population studied (79 cats in total). Urine RT-PCR was performed in 16
azotemic cats (designated A1-A16) and 24 nonazotemic cats (designated
S1-S11; and H1-H13). Serology was performed in 72 cats in total (desig-
nated A1-A16; S1-S8; H1-H9; H14-H52). 33/40 (82%) cats had concur-
rent serology and urine RT-PCR performed.
A power calculation performed based on the prevalence of FeMV
in cats with and without TIN1 indicated that the study needed a
minimum of 14 cats per group to be 80% powered to find significant
differences between the groups.
2.2 | RT-PCR and nested RT-PCR amplification
RNA isolation was performed using the QIAamp Viral RNA Mini Kit
(Qiagen, Manchester) following the manufacturer’s instructions.
We used a broadly reactive PCR assay reported to detect all
known paramyxoviruses.2 The primer targets correspond to highly con-
served regions of the genome (L protein) and can detect 25 reference
viruses from the paramyxovirus family. The published method was
slightly modified by using random hexamers to generate the cDNA as
we found this resulted in greater and more consistent yields of
PCR product. cDNA synthesis was performed using Superscript III
(Invitrogen, Carlsbad, California) following the manufacturer’s instruc-
tions. 10 ml of the cDNA reaction was used as input for the 1st round
of seminested PCR using 1 lM forward (PAR-F1) and reverse primers
(PAR-R) subjected to 40 cycles of amplification (948C for 15 seconds,
488C ramping to 508C for 30 seconds, 728C for 30 seconds) and a final
extension at 728C for 7 minutes. The 2nd amplification in the semi-
nested PCR used 2 mL of template from the 1st amplification under the
same conditions as the 1st except the forward primer PAR-F2 replaced
PAR-F1.
The final PCR products were visualized by ultraviolet light after
electrophoresis on a 2% agarose gel containing 0.5 mg/mL ethidium
bromide.
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2.3 | DNA sequencing
Bands of the appropriate size (500 bp) were excised from the gel and
DNA was extracted using the Purelink Quick Gel Extraction Kit (Invitro-
gen, Carlsbad, California) before being sent for Sanger sequencing using
the primers PAR-F2 and PAR-R (Source BioScience, Cambridge, UK).
The sequences were compared with the complete nonredundant
nucleotide database using BLASTn (http://blast.ncbi.nlm.nih.gov).
2.4 | Sequence alignment
Multiple sequence alignment and phylogeny representation of the
amplified region of the L gene were performed using the MUSCLE,
GBlocks, PhyML, and TreeDyn tools as implemented in the “One-click”
mode of Phyogeny.fr.21 The alignment was displayed using MView.22
2.5 | N protein PCR amplification
The N protein is highly conserved with >90% nucleotide sequence
identity amongst the FeMVs but distinct from other morbilliviruses.4
The N protein has previously been assessed by indirect
immunofluorescence assay for seroprevalence studies of FeMV where
a seroprevalence of 21% was identified.16 Amplification of the N gene
of FeMV from urine sample RNA was performed using nested PCR.
cDNA was produced as described above (except for using primer
FMV_N_For (50GAGGRGRAGGAATCAGGTATTTCASAATG 30) instead
of random hexamers). The N gene was amplified for 30 cycles (958C
for 30 seconds, 598C for 30 seconds, 728C for 60 seconds) followed by
728C for 10 minutes using 0.5 mM of each primer FMV_N_For and
FMV_N_Rev (50CRGTYGTGAACYTTGAGGTCCTAAGT 30), 2 mL tem-
plate cDNA and 2.5U DreamTaq DNA Polymerase (Thermo Scientific).
The secondary nested PCR procedure was carried out as above
except for using pASG-IBA144 insertion primers (N_pASG_N_termF
(50AGCGCGTCTCCAATGTCTAGTCTATTGAGGTCACTTGCTG30) and
N_pASG_Rev (50AGCGCGTCTCCTCCCTTTTAGAAGGTCAGTATCATT
ATAATG 30; annealing temperature 618C). These are designed to fuse
the full-length N gene open reading frame in frame with the N-terminal
ompA-twin Strep tag and the C-terminal 6xHis tag intended to be used
for subsequent protein expression and purification. PCR products were
subsequently purified using a QIAQuick PCR Purification kit, digested
with Esp31, ligated into pASG-IBA144, cloned in E. coli DH5-alpha
TABLE 1 Summary of clinical status, PCR, and WB results
CKD status
(A versus NA) FPV PCR FeMV PCR WB
Number
of cats Sample numbers
A NEG POS SP 1 A1
A NEG NEG SP 1 A2
A NEG NEG P 2 A3, A4
A NEG NEG WP 2 A5, A6
A NEG NEG HB 2 A7, A8
A NEG NEG NEG 8 A9-A16
NA NEG POS SP 2 S1, H1
NA NEG POS P 2 S2, H3
NA NEG NEG P 1 S3
NA NEG NEG WP 5 S4, S5, H4, H5, H6
NA NEG NEG NEG 5 S7, S8, H7, H8, H9
NA POS NEG NEG 1 S6
NA POS NEG NT 2 S9, H10
NA NEG NEG NT 5 S10, S11, H11, H12, H13
NA NT NT POS 9 H14, H17, H21, H24, H27, H28, H35, H37, H45
NA NT NT SP 3 H16, H31, H43
NA NT NT WP 17 H15, H19, H20, H22, H23, H25, H26, H36, H38,
H39, H40, H41, H46, H48, H49, H50, H51
NA NEG NEG SP 1 H2
NA NT NT HB 1 H18
NA NT NT NEG 9 H29, H30, H32, H33, H34, H42, H44, H47, H52
RT-PCR was performed on 16 azotemic cats (A1-A16) and 24 non-azotemic cats (S1-S11, H1-H13). serology was performed on 72 cats (A1-A16, S1-
S8, H1-H9, H14-H52). FPV, feline paramyxovirus; FeMV, feline morbillivirus; A, azotemic; NA, nonazotemic; SP, strong positive; POS, positive; WP,
weak positive; NEG, negative; NT, not tested; HB, high background (therefore, could not be scored definitively).
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(Invitrogen) and subsequently transferred into E. coli BL21 DE3. The
complete sequence of the N-gene and associated affinity tags for the
chosen clone was subsequently verified.
2.6 | Expression and partial purification of
FeMV N protein
One milliliter of overnight starter culture was added to 10 mL LB
Amp100 medium and incubated at 378C shaking at 225 rpm until the
OD600 reached 0.4-0.8 at which point 200 mg/mL of anhydrotetra-
cycline was added to induce protein expression from the vector. At
the optimum time-point for maximum soluble protein (2 hours post-
induction), the E. coli BL21 DE3 cells were pelleted and resuspended
in 3 mL/g wet weight of pellet of lysis buffer (0.15 M NaCl, 10%
sucrose, 50 mM Tris-HCl pH 7.5, 0.1% Triton X-100 and Lysozyme
at 0.2 ng/mL). and incubated for 30 minutes on ice. Subsequently,
0.5 mL of Benzonase (Sigma 250 units mL) was added to the sample
for a further 10 minutes to digest DNA to reduce sample viscosity.
The supernatant was harvested by centrifugation at 10 000g for 25
minutes at 48C. The pellet fraction (which contained 50% of the
yield) was solubilized using 8 M urea in 10 mM Tris-HCl pH 8 (5 mL/
g wet weight of pellet) incubated for 60 minutes at RT. After incuba-
tion, the mixture was centrifuged at 10 000g for 25 minutes and the
solubilized protein in the supernatant collected. The soluble and
solubilized fractions of N protein were purified via the 6xHis tag,
using Ni-NTA Magnetic Agarose Beads following the manufacturer’s
standard protocol.
2.7 | SDS PAGE and Western blotting (WB)
SDS PAGE was performed using a 8% resolving gel and 4.5% stacking
gel under reducing conditions. After semidry transfer to a nitrocellulose
membrane and blocking [5% nonfat-dried milk powder dissolved in
19 mM Tris pH 7.4. 137 mM NaCl, 2.7 mM KCl, 0.1% Tween20
(TBST)], the blot was probed for His-tagged N protein expression and
enrichment using 1:500 mouse anti-6xHis antibody (Merck Millipore/
cat #05–949) followed by a 1:2000 dilution of horseradish peroxidase
conjugated goat anti-mouse IgG secondary antibody (Sigma-Aldrich,
cat #A3673).
To screen multiple cat sera simultaneously for reactivity to the N-
protein, 50 mL of Ni-NTA bead-enriched N protein was loaded onto a
full gel-width well, electrophoresed, transferred, and blocked as before.
The nitrocellulose filter was loaded into a 20-channel Biorad Multiscreen
unit. The cat sera (diluted 1:100 with TBST10.5% Roche Blocking Rea-
gent) were loaded separately into the individual channels and incubated
for 2 hours at room temperature. A mixture of mouse anti-His tag 18
antibody and anti-mouse HRP 28 antibody was added to the end channel
to provide a marker for the migration of the His-tagged N protein band
(s). The filter was processed as before except for using 1:1000 dilution
of BioRad horseradish peroxidase conjugated goat anti-cat as the sec-
ondary antibody (Bio-RAD/Cat #AA126P). Blots were developed using
the BM Chemiluminescence Blotting kit following the manufacturer’s
instructions. Luminescence imaging was recorded using a Biorad Chemi-
doc MP imager (exposure time of 2 seconds).
A primary assay validation of the WB assay was performed using
sera from all 5 cats that tested positive for FeMV in urine via PCR, 1
cat that was positive for non-FeMV and 5 FeMV RNA negative cats to
test for reactivity to the 58 kDa doublet (Figure 1).
2.8 | Statistical analysis
Comparisons between groups were made using Fisher’s exact test and
Mann Whitney U test were used as appropriate. Data are presented
as median [25th, 75th percentiles] and statistical significance defined
as <.05.
3 | RESULTS
3.1 | Clinical description of the cohort
A total of 40 cats were included in the 1st part of the study (Table 1).
Sixteen cats were in the azotemic CKD group and 24 cats in the nona-
zotemic group. The azotemic CKD group (A1-A16) comprised 6 female
neutered and 10 male neutered cats. Breeds represented in this group
included 11 domestic short-haired cats, 2 domestic long-haired cats
plus 1 British Short Hair, Burmese, and Tonkinese cat, respectively. The
age of the cats ranged from 8.7 to 18.5 years old (median: 12.5 years
FIGURE 1 WB using Biorad Multiscreen apparatus. Individual cat
sera (designated A1, H7, H4, etc) were tested for binding to E. coli
expressed, NTA-bead purified His-tagged FeMV N protein. Urine
RT-PCR status for each sample is indicated by1or –. * sample S6
was positive for non-FeMV viral RNA. The 60 kDa band of inter-
est is indicated by the black arrow
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[11.3, 16.4]). The median serum urea concentration was 42.3 mg/dL
[29.9, 50.1] or 15.1 mmol/L [10.7, 17.9] and median serum creatinine
concentration was 2.08 mg/dL [1.82-2.57] or 184 mmol/L [161, 227].
Thirteen cats had a serum creatinine value between 1.58 and 2.82 mg/
dL (140 and 250 mmol/L) (corresponding to IRIS stage II) and 3 cats had
serum creatinine value between 2.82 and 4.98 mg/dL (250–440 mmol/
L; corresponding to IRIS stage III).
The nonazotemic group (S1-S11 and H1-H13) comprised 11
female neutered and 13 male neutered cats. Breeds represented in this
group included 3 domestic long-haired cats and 21 domestic short-
haired cats. The age of the cats ranged from 8 to 19 years old (median:
11 years [9.8, 14.0]). Median serum urea concentration was 29.4 mg/
dL [26.6, 35] or 10.5 mmol/L [9.5, 12.5] and median serum creatinine
concentration was 1.49 mg/dL [1.23, 1.59] or 132 mmol/L [109, 141].
3.2 | Detection and characterization of paramyxovirus
RNA in urine samples
Morbillivirus L gene sequences were detected by RT-PCR in 5 out of
40 of the urine samples (Table 1). Analysis of the aligned sequences
(Figure 2) showed that they were all highly similar (Table 2) and all 5
were phylogenetically most closely related to the USA strain FeMV-
US1 (accession number KR014147) with the Hong Kong strains 761U
and 776U (JQ411014 and JQ411015, respectively) being the next
most closely related. Samples A1, S2, and H1 clustered as a single
group with FeMV-US1. S1 and H3 mapped as two further distinct iso-
lates. The N gene coding region cloned from sample S1 also most
closely matched these three isolates (see below). Three distinct non-
FeMV paramyxoviruses were also detected (samples S6, S9 and H10)
that were most closely related to strain FPV-MSi-2014 from Germany
(accession number KP 159805). Of these, H10 and S6 formed a distinct
subgroup. S9 was the most closely related to FPV-MSi-2014.
3.3 | Correlation of paramyxovirus RNA in urine and
health status
FeMV RNA detection was not significantly different between azotemic
CKD and non-azotemic groups (1/16 versus 4/24 respectively; P5 .36.
Table 1). Although the non-FeMV paramyxoviruses were only detected
in the nonazotemic group, this difference from the azotemic group was
not significant (3/24 versus 0/16, respectively; P5 .15; Table 3).
To assess the effect of urine concentration on the likelihood of
detecting FeMV and non FeMV paramyxovirus, the proportion of cats
with USG >1.035 that were positive for FeMV and non-FeMV paramyx-
ovirus in their urine was compared with that of cats with USG <1.035.
FeMV detection was not significantly different between cats in the USG
<1.035 and USG >1.035 group (2/12 versus 2/12; P51.0). Non-FeMV
paramyxovirus detection was also not significantly different between
USG <1.035 and USG >1.035 group (1/12 versus 2/12; P5 .55).
3.4 | N Protein expression
The N sequence from cat S1 (a nonazotemic cat testing positive for
FeMV RNA) was cloned and sequenced. It was most closely related to
the 761U and US1 strains (1538 and 1537 out of 1557 nucleotide
identity; 514 and 515 out of 518 amino acid identity, respectively). WB
analysis using antibody to the C-terminal 6xHis-tag introduced during
cloning showed a doublet band straddling the 58 kDa prestained
FIGURE 2 Phylogenetic tree showing comparison of FeMV and non-FeMV sequences to previously reported sequences. GenBank
accession numbers A1 (MG640027), S9 (MG640028), H10 (MG640029), H1 (MG640030), S6 (MG640031), S1 (MG640032), H3
(MG640033), and S2 (MG640034)
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marker band (the predicted size of the 57 kDa N protein plus the tags
is 63.6 kDa) plus several smaller presumed N-terminal truncation prod-
ucts 29–32 kDa in size (Figure 3A). NTA-bead purification of the pro-
tein led to a substantial enrichment of the 60 kDa doublet in the
primary eluate and the detection of numerous lower molecular weight
products (Figure 3B). A 2nd elution from the column released only a
small additional amount the protein. A substantial proportion remained
associated with the beads that was released upon boiling in sample
buffer.
The partially purified protein was used as antigen to analyze single
dilutions of individual cat sera by WB (Figure 4). The cat sera reacted
with a variety of different sized proteins in addition to the 60 kDa
doublet on the blot. Some of these may be N protein degradation prod-
ucts but others are likely to be E. coli proteins present in the partially
purified antigen. All the sera from the cats that were PCR-positive for
viral RNA in their urine were also highly reactive to the 60 kDa dou-
blet (cats A1, H1, S1, H3, and S2). Cat H2 (which was FeMV negative)
was also strongly positive (as was H6 to a lesser extent). The remaining
sera from RNA negative cats in this figure had low level (weak positive
or negative) reactivity to the 60 kDa doublet. Cat S6, which was posi-
tive for non-FeMV paramyxovirus was negative on WB. The presence
of FeMV RNA in urine was therefore predictive of N protein reactivity
by WB, but this correlation did not extend to all the WB positive
samples.
Further screening of sera from both azotemic and normal cats was
performed (Figure 4) and in total 22/72 sera tested positive or strongly
positive by WB and a further 24 had detectable but weak positive
reactivity. However, the level of reactivity was quite variable, with the
majority of cats showing weak positive reactivity compared to cat A1
which was routinely included as a benchmark for strong positivity.
Three cats (two azotemic and one nonazotemic) had high background
on the WB and so were excluded from further analysis. 6/14 (43%)
azotemic cats and 40/55 (73%) nonazotemic cats were seropositive on
WB (P5 .06).
4 | DISCUSSION
Our study identified RNA from FeMV and non-FeMV paramyxoviruses
in the urine of cats, thus confirming the presence of these viruses in
cats in the United Kingdom. In addition, a high percentage of UK cats
had detectable serum antibodies to FeMV (31% or 64% depending on
whether the weak positives were included), indicating that a substantial
proportion of UK cats have evidence of exposure to this/or a related
virus. However, we did not detect an association between urinary
excretion of these viruses, or the presence of serum anti-FeMV anti-
bodies, and the presence of azotemic CKD. This is in contrast with the
previously documented association between FeMV and the presence
of histopathologically confirmed TIN (the most common lesion in cats
with CKD),1 but is in agreement with a subsequent study from Japan
which found no association between TIN and FeMV infection.16 In
both of these previous studies, FeMV status was determined by a com-
bination of RT-PCR, serology and immunohistochemistry.
Recently, Sieg et al6 reported an association between urinary
excretion of FeMV and CKD in cats, which is in contrast to the findings
of our study. However, it should be noted that the Sieg study did not
use a homogenous group of biochemically confirmed azotemic cats, as
the CKD group also included cats diagnosed with feline lower urinary
tract disease (FLUTD), nephritis, hematuria, urolithiasis, cystitis,
TABLE 3 Paramyxoviral status (FeMV and non-FeMV
paramyxoviral positive cats) of azotemic (A1-A16) and nonazotemic
CKD groups.
Paramyxoviral status
Azotemic CKD
(A1-A16)
Non-azotemic CKD
(S1-S11; H1-H13)
Non-FeMV
paramyxovirus
positive
0/16 (0%) 3/24 (13%)
FeMV positive 1/16 (6%) 4/24 (17%)
TABLE 2 Comparison of percentage nucleotide sequence identity between the aligned sequences identified in our study and their nearest
paramyxovirus relatives, FmoPV-US1 (KR014147) and FPV-MSi-2014 (KP159805)
Comparison of
sequences MSi-2014 S9 H10 S6 US1 S2 Al S1 H1 H3
Msi-2014 100 98 92 92 73 73 73 72 72 72
S9 98 100 91 92 73 73 73 72 72 72
H10 92 91 100 98 73 67 74 73 73 67
S6 92 92 98 100 72 72 73 72 72 71
US1 73 73 73 72 100 99 99 97 99 98
S2 73 73 67 72 99 100 99 97 99 99
A1 73 73 74 73 99 99 100 97 99 98
S1 72 72 73 72 97 97 97 100 97 96
H1 72 72 73 72 99 99 99 97 100 98
H3 72 72 67 71 98 99 98 96 98 100
Cells are shaded to indicate the isolates belonging to the FeMV (light shading) and non-FeMV (dark shading) groups.
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urostase, chronic kidney failure, chronic nephropathy, proteinuria, and
bacteriuria. In contrast, our study excluded cats with evidence of other
etiologies such as lower urinary tract inflammation and only included
cats with biochemical evidence of renal azotemia.
Whilst our results suggest that exposure to, or urinary excretion
of, FeMV is not associated with the presence of azotemic CKD in cats,
this does not entirely rule out the possibility of a causal association
between renal FeMV infection and CKD. It is possible that the infection
could result in intermittent shedding or could trigger a self-sustained
immunopathological process leading to the development of TIN and
CKD even after the viral infection had been completely resolved (both
possibilities manifesting as an RNA PCR negative, WB positive,
azotemic CKD result). FeMV infected nonazotemic cats (initially scored
as RNA PCR positive, WB positive, CKD negative) might subsequently
develop azotemic CKD. Longitudinal observational studies would be
required to investigate the association between exposure to, or infec-
tion with, FeMV and the eventual development of azotemic CKD.
The seropositive rate of UK cats was higher (31%-64%) than has
been reported in previous studies (21%-28%).1,4,16,23 All of the previ-
ous studies evaluated the seroprevalence in Japanese cat populations,
therefore it appears that a greater number of UK cats have been
exposed to the virus. This could reflect increased proportion of outdoor
cats given that a greater proportion of cats with street access had
detectable FeMV in urine in a recent study.10 It has also been reported
FIGURE 4 Further WB screening of 1/100 dilutions of sera from azotemic and nonazotemic cats showing strong positive, positive, weak
positive and negative reactivity to NTA-bead purified his-tagged FeMV N protein. Data are summarized in Table 1. Lane M was developed
using a mixture of mouse anti-6xHis 18 Ab and goat anti-mouse HRP 28 antibody
FIGURE 3 A, WB analysis of His-tagged N protein expression in E. coli before and after induction with anhydrotetracycline. Protein reac-
tive with mouse-anti 6xHis IgG is present in the soluble and insoluble fractions after induction. B, WB analysis after NTA-bead purification
showing N protein concentrations in the initial lysate pre and post-binding to the beads. Equal total protein levels were loaded on lanes 1,
2, and 5 to permit assessment of the depletion because of binding to the beads (compare lanes 1 and 2) and subsequent enrichment post
elution (lane 5). A substantial amount of protein remained bound to the bead after two rounds of elution (lane 7)
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that there can be antigenic cross-reactivity between FeMV and canine
distemper virus,4 and 10% of serum samples from cats had neutraliz-
ing antibodies against CDV,24 therefore it is also possible that the
higher seropositive rate in our cats could partly be explained by the
presence of anti-CDV antibodies rather than anti-FeMV in some cats.
If the weak positive samples were excluded, the 31% prevalence is
more consistent with the results from Japan. The overall prevalence of
FeMV in the urine of UK cats was 13%, which was similar to the preva-
lence documented in Hong Kong (12%)7 and Japan (6%-23%)3–5,16,25
but higher than that documented in Turkey (3%).10
Many cats with positive or strong positive levels of anti-FeMV
antibodies did not have detectable FeMV in the urine. This could
reflect previous infection with the virus that has subsequently been
cleared or could reflect active infection without urinary FeMV excre-
tion at the time of sampling.16 WB analysis in our study documented a
seroprevalence of 31%-64% and also revealed a high correlation
between positive FeMV urinary PCR results and seropositivity. Simi-
larly, in Hong Kong, a significantly higher proportion (76.7%) of FeMV
RT-PCR positive cats were seropositive against FeMV N protein com-
pared to FeMV RT-PCR negative cats (19.4%).1
Phylogenetic analysis of the L protein sequences identified in our
study demonstrated that the most closely related FeMV sequences
corresponded to those in Japan and the USA. The sequence variation
in this region of the virus was so limited that it was not possible to
determine the likely recent ancestral relationship.
The diagnosis of azotemic CKD in our study was based on the
measurement of serum creatinine concentration, which is a relatively
insensitive indirect marker of GFR, because serum creatinine concen-
trations only increase above reference intervals when 75% of func-
tional renal mass lost. Direct measurement of GFR was not possible in
the 1st opinion clinics where these samples were collected. One study
has indicated that increased concentrations of symmetric dimethylargi-
nine (SDMA) occur earlier in the time course of progressive feline CKD
in comparison to increased concentrations of serum creatinine.26
Future studies investigating the seroprevalence of FeMV in cats with
and without CKD when using this novel biomarker could be warranted.
There are a several limitations of our study. We have not confirmed
the presence of live virus by viral isolation studies, however previous
studies have identified live virus from all RNA positive cats.1,4 Further-
more qRT-PCR has been reported to be more sensitive than conven-
tional PCR for detecting FeMV RNA in urine samples.25 However, we
repeated our assays using the qRT-PCR method but did not identify any
additional cats with urinary FeMV that were not detected by our semi-
nested PCR assay (data not shown). It would also have been interesting
to document if FeMV infection was persistent in FeMV positive cats in
the present study. Persistence of viral shedding over a 2 week and 15
month period has been reported in two previous studies,7,8 however
regrettably we were not able to obtain follow up samples from any RT-
PCR positive cats in the present study. Bias in virus detection and sero-
logical screening may have been introduced by the assessment of solely
geriatric cats, however, this represents the population in which CKD
occurs in general. Although there were only small number of cats
included, power calculations suggested that the group sizes were
adequate to detect significant differences in the prevalence of FeMV
between azotemic and non-azotemic cats, if the proportion of cats with
CKD that had FeMV infection was similar in the UK and Hong Kong.
Histopathology would have been required to further investigate if there
is an association between TIN and FeMV detection, however this would
have required renal biopsy, which is not currently recommended for the
diagnostic workup of most cases of feline CKD. It also is possible that
some nonazotemic cats had subclinical nonazotemic CKD, however
direct measurement of GFR was not possible in the 1st opinion clinics
where these samples were obtained. It is also possible that in some
cases FeMV RNA degradation may have occurred during transport of
urine samples to our laboratory or during freezing. However, a previous
study documented that freeze-thawing samples did not affect virus
titers and FeMV was stable at environmental temperatures.27 Further-
more, it would have been useful to perform complete viral genome
sequencing to allow for further studies evaluating the genetic diversity
of morbillivirus compared to other strains detected worldwide. How-
ever, detecting multiple differences in the highly conserved L gene
region suggests that these viruses were genetically distinct.
In conclusion, our study reports the detection of RNA from FeMV
and non-FeMV paramyxoviruses in the urine of cats in the UK. No
association was found between the presence of clinically appreciable
(azotemic) CKD and urinary excretion or past exposure to these viruses
(seroprevalence). Despite a lack of association with CKD, the high sero-
prevalence of paramyxovirus in this cohort suggests that further stud-
ies are required to further evaluate the seroprevalence of both FeMV
and feline paramyxovirus in the UK cat population and establish if
these viruses are associated with other diseases.
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